Figure 3.

Box-plots showing the percentage of (a) CD28^null/interferon (IFN)-γ⁺/CD4⁺ (clear bars) and CD28^null/IFN-γ⁺/CD8⁺ T cells (grey bars) in control subjects (C), stable transplant patients (S) and patients with bronchiolitis obliterans syndrome (BOS) (B). There was a significant increase in the percentage of CD28^null/IFN-γ⁺/CD4⁺ and CD28^null/IFN-γ⁺/CD8⁺ T cells in patients with BOS compared with stable transplant patients and controls. There was a significant increase in the percentage of CD28^null/IFN-γ⁺/CD8⁺ T cells in controls, stable patients and patients with BOS compared with CD28^null/IFN-γ⁺/CD4⁺ cells (dotted line). (b) CD28^null/tumour necrosis factor (TNF)-α⁺/CD4⁺ (clear bars) and CD28^null/TNF-α⁺/CD8⁺ T cells (grey bars) in control subjects (C), stable transplant patients (S) and patients with BOS (B). There was a significant increase in the percentage of CD28^null/TNF-α⁺/CD4⁺ and CD28^null/TNF-α⁺/CD8⁺ T cells in patients with BOS compared with stable transplant patients and controls. There was a significant increase in the percentage of CD28^null/TNF-α⁺/CD8⁺ T cells in controls, stable patients and patients with BOS compared with CD28^null/TNF-α⁺/CD4⁺ cells (dotted line). (c) CD28^null/IL-2⁺/CD4⁺ (clear bars) and CD28^null/IL-2⁺CD8⁺ T cells (grey bars) in control subjects (C), stable transplant patients (S) and patients with BOS (B). There was a significant decrease in the percentage of CD28^null/IL-2⁺/CD4⁺ and CD28^null/IL-2⁺/CD8⁺ T cells in stable transplant patients compared with controls. There was a significant increase in the percentage of CD28^null/IL-2⁺/CD4⁺ and CD28^null/IL-2⁺/CD8⁺ T cells in patients with BOS compared with stable transplant patients.